Zacks Research Analysts Lift Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Zacks Research boosted their Q1 2025 EPS estimates for shares of BioMarin Pharmaceutical in a report released on Wednesday, January 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $0.61 for the quarter, up from their previous estimate of $0.60. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.68 EPS, Q2 2026 earnings at $0.84 EPS and Q3 2026 earnings at $0.89 EPS.

Several other equities analysts also recently issued reports on BMRN. Stifel Nicolaus reduced their price objective on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Truist Financial dropped their price target on shares of BioMarin Pharmaceutical from $118.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Wedbush raised shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. Wolfe Research started coverage on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. They issued an “outperform” rating and a $95.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

BioMarin Pharmaceutical Trading Down 1.5 %

NASDAQ BMRN opened at $67.38 on Friday. BioMarin Pharmaceutical has a one year low of $61.15 and a one year high of $96.64. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. The firm’s fifty day moving average is $65.83 and its two-hundred day moving average is $75.10. The firm has a market cap of $12.84 billion, a PE ratio of 40.35, a P/E/G ratio of 0.65 and a beta of 0.29.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The company had revenue of $746.00 million during the quarter, compared to analysts’ expectations of $703.37 million. During the same period last year, the firm earned $0.26 earnings per share. BioMarin Pharmaceutical’s revenue was up 28.4% on a year-over-year basis.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the stock. BOKF NA acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter worth approximately $31,000. nVerses Capital LLC acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. TD Private Client Wealth LLC raised its holdings in BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after buying an additional 186 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $47,000. Finally, Meeder Asset Management Inc. raised its holdings in shares of BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 663 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Charles Greg Guyer sold 5,278 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the transaction, the executive vice president now owns 68,909 shares in the company, valued at $4,573,490.33. This represents a 7.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.85% of the stock is owned by corporate insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.